Valneva (VALN) Projected to Post Quarterly Earnings on Wednesday

Valneva (NASDAQ:VALN - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect Valneva to post earnings of ($0.40) per share and revenue of $41.80 million for the quarter.

Valneva (NASDAQ:VALN - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The firm had revenue of $56.48 million for the quarter, compared to analysts' expectations of $55.64 million. On average, analysts expect Valneva to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Valneva Price Performance

Shares of VALN stock traded up $0.19 during mid-day trading on Friday, reaching $6.57. The stock had a trading volume of 60,571 shares, compared to its average volume of 36,693. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The business has a 50-day simple moving average of $6.81 and a 200 day simple moving average of $5.72. The company has a market cap of $549.49 million, a P/E ratio of -50.54 and a beta of 1.85.

Wall Street Analyst Weigh In

Several analysts have issued reports on VALN shares. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price target on shares of Valneva in a report on Tuesday, April 15th. Guggenheim lowered their target price on Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a report on Monday, March 24th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.